Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subretinal vs intravitreal tPA + Conbercept + C3F8 for acute submacular hemorrhage
ChiCTR2400089058Phase 4Recruiting
- Sponsor
- Dongguan Guangming Ophthalmology Hospital
- Start
- Aug 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of conbercept, tissue-plasminogen activator and perflutren in submacular hemorrhage (SMH), exudative macular degeneration and polypoidal choroidal vasculopathy (PCV) (2 arms), sponsored by Dongguan Guangming Ophthalmology Hospital. Primary endpoints: Displacement and absorption of submacular hemorrhage, Visual acuity and 3 more. Started Aug 2024; status: recruiting.
02
Drugs
conbercepttissue-plasminogen activatorperflutren
03
Conditions
submacular hemorrhage (SMH)exudative macular degenerationpolypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on ChiCTR2400089058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089058.